The European Union has established an 11% growth target for clinical trials, aiming to provide an estimated 35,000 additional patients with access to cutting-edge medical treatments. This initiative seeks to reverse a decade-long decline in the region's share of global industry-sponsored trials, which fell from 22% to 12% between 2013 and 2023, while China's participation more than doubled. The EU plans to add 500 multinational trials over the next five years.
Achieving these targets is projected to inject €4 billion annually into the EU economy and create 18,000 jobs. An even more ambitious goal of a 50% increase in trial activity could unlock €17.9 billion and create 158,000 trial positions, bringing Europe closer to parity with the United States and China.
Industry-sponsored trials currently generate €35.7 billion in annual economic value across the European Economic Area, with significant contributions from Germany, France, and Belgium. These trials are crucial for scientific advancement, leading to breakthroughs that can reach patients 10-15 years earlier than through standard market channels.
Recent regulatory efforts, including the EU Biotech Act and Accelerating Clinical Trials in the EU (ACT EU), are designed to streamline the approval process. By consolidating national rules into a single, unified system, the EU aims to attract substantial pharmaceutical investment back to the continent and foster a more robust research and development ecosystem.